QS Investors’s Cardlytics CDLX Stock Holding History

QS Investors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$7K	–	1236
2020 Q2	$7K	Hold	10	–	–	﹤0.01%	1578
2020 Q1	$4K	Buy	+10	New	+$7.08K	﹤0.01%	1620

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

QS Investors's CDLX Position: Q3 2020 in Review

QS Investors sold out of Cardlytics (CDLX) in Q3 2020, closing a stake of 10 shares — an estimated $7K sold.

QS Investors first reported a position in CDLX in Q1 2020 and held it in 2 quarters. The position peaked at $7K in Q2 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2020.

QS Investors reported no remaining Cardlytics position as of Q3 2020 after selling out during the quarter.
QS Investors sold 10 Cardlytics shares in Q3 2020, an estimated $7K.
QS Investors first reported a position in Cardlytics in Q1 2020 and held it in 2 quarters.
QS Investors's Cardlytics position peaked at $7K in Q2 2020.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.